PHARMACOLOGIC REDUCTION OF ALCOHOL CONSUMPTION IN ALCOHOLIC PATIENTS

最近的研究表明，酒精的消费是由 几种相互作用的神经递质，包括多巴胺和 血清素系统。在随机双盲设计中，慢性 酒精中毒门诊患者将接受L-多巴或L-5-羟色氨酸， 均与外周脱羧酶抑制剂卡比多巴或 L服用安慰剂一年。在这一年里，酒精消费- 情绪、肝功能、饮酒欲望、精神状态、 心理社会功能和服药依从性将是 定期评估。在进入研究之前， 在3个月后，在1年内，将执行以下程序 进行药物疗效评估：(1)行为评估；(2) 药物、单胺、激素和 血液和脑脊液中的多肽；(3)立位改变 心率、血压和血浆去甲肾上腺素 浓度；以及(4)血浆加压素反应的评估 到生理盐水输注。酒精消费的变化将与 生化和行为参数。

Recent studies indicate that alcohol consumption is regulated by several interacting neurotransmitters, including the dopamine and serotonin systems. In a randomized double-blind design, chronic alcoholic outpatients will receive L-DOPA or L-5-hydroxytryptophan, both with the peripheral decaboxylase inhibitor carbidopa or placebo for a l-year period. During this year, alcohol consump- tion, liver function, craving for alcohol, mental status, psychosocial functioning, and compliance with medication will be assessed at regular intervals. Prior to entry into the study, after 3 months, and at 1 year, the following procedures will be conducted to measure drug effects: (1) behavioral evaluation; (2) determination of concentrations of drugs, monoamines, hormones, and peptides in blood and cerebrospinal fluid; (3) orthostatic changes in heart rate, blood pressure, and plasma norepinephrine concentrations; and (4) assessment of plasma vasopressin response to saline infusion. Changes in alcohol consumption will be related to biochemical and behavioral parameters.